Drug Information

Drug General Information
Drug ID
D0K9MY
Former ID
DCL000639
Drug Name
Saxagliptin
Synonyms
Onglyza; BMS 477118-11; BMS-477118; Kombiglyze XR (TN); OPC-262; Onglyza (TN); BMS-477118-11; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Approved [530677], [541462]
Company
Bristol-Myers Squibb; AstraZeneca
Formula
C18H25N3O2
InChI
InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
InChIKey
QGJUIPDUBHWZPV-SGTAVMJGSA-N
CAS Number
CAS 361442-04-8
PubChem Compound ID
11243969
PubChem Substance ID
16328544, 16675586, 23422497, 42323525, 46512075, 57304394, 75512904, 92722527, 96025679, 99443245, 103500900, 104096574, 104253199, 121147387, 121362351, 123051077, 124758670, 124772084, 126618190, 126644889, 136340362, 137251549, 139567127, 144076400, 144206461, 152035966, 160655903, 160967860, 162011574, 162164961, 175267813, 175610961, 178102934, 184811995, 223668663, 223705237, 224543974, 225361148, 226407286, 246280642, 251970941, 252154978, 252447400
SuperDrug ATC ID
A10BH03
Target and Pathway
Target(s) Dipeptidyl peptidase IV Target Info Inhibitor [530677], [537022], [550288]
KEGG Pathway Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
References
Ref 530677Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
Ref 541462(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6316).
Ref 530677Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
Ref 537022Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).